Expedeon signs license agreement for use of Lightning-Link technology

Expedeon AG, today announced it has signed a supply and license agreement with Cell Guidance Systems, a developer of therapeutic products for medicine and life science research, for use of Expedeon’s proprietary Lightning-Link® Rapid Biotin technology in the development and production of TRIFic (Time-Resolved Immunofluorescence Exosome Detection Assay) immunoassays.

Cell Guidance Systems has already benefitted from the application of Expedeon’s Lightning-Link® technology for over two years, and under this new agreement, Expedeon becomes preferred immunoreagent supplier to the company.

Cell Guidance Systems’ TRIFic rapid detection assay provides quantitative data from purified and unpurified samples, including direct measurements of exosomes in plasma. TRIFic exosome assays are available for widely used markers of exosomes, including the tetraspanin proteins CD9, CD63 and CD81, and provides high sensitivity detection levels which are clear and consistent over a wide range of samples.

The Expedeon Lightning-Link® Rapid Biotin kit enables the rapid, direct biotinylation of antibodies, proteins and peptides, or any other biomolecule with an available amine group, with 100% recovery of materials. The kit is optimized for assays in which the biotinylated protein is captured by streptavidin immobilized on a surface.

The kit requires only 30 seconds hands-on time and the conjugates are ready to use in under 20 minutes. The technology is fully scalable from 10ug to 1g or over, and is stringently QC tested for consistent high quality and excellent batch-to-batch reproducibility.

Using Expedeon’s Lightning-Link® biotin technology will enable Cell Guidance Systems to manufacture TRIFic detection assays on-demand with highly reproducible and scalable results. Cell Guidance Systems will benefit from cost savings on detection antibodies and secondary immunoreagents, plus improved productio.n yields and enhanced quality of immunoassay handling.

We have been working with Cell Guidance Systems for several years and are delighted to strengthen the relationship. Our technology provides a rapid, easy to use, efficient method of labeling antibodies and we are confident it will serve Cell Guidance Systems very well in the development and production of their TRIFic detection assay kits.

This latest agreement follows a number of license and supply agreements with various partners for Lightning-Link®, underlining the increasing demand in academia and industry for our proprietary solutions, which help drive the life sciences research sector.”

Dr  Heikki Lanckriet, CEO and CSO of Expedeon

TRIFic kit is an exquisitely sensitive europium time resolved immunofluorescence assay for exosome markers. The Lightning-Link® Rapid Biotin technology is used to generate stable biotin conjugates as components of this platform.

We have found Expedeon’s cutting edge technologies to be reliable and meet the high standards that our customers demand, and will be invaluable in ensuring the TRIFicdetection assay kits enable researcher to save time and costs.”

Dr. Laur-Alexandru Botos, Senior Research Scientist, Cell Guidance Systems

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Expedeon. (2019, June 20). Expedeon signs license agreement for use of Lightning-Link technology. News-Medical. Retrieved on August 24, 2019 from https://www.news-medical.net/news/20190109/Expedeon-signs-supply-and-license-agreement-with-Cell-Guidance-Systems-for-use-of-Lightning-Linkc2a0technology.aspx.

  • MLA

    Expedeon. "Expedeon signs license agreement for use of Lightning-Link technology". News-Medical. 24 August 2019. <https://www.news-medical.net/news/20190109/Expedeon-signs-supply-and-license-agreement-with-Cell-Guidance-Systems-for-use-of-Lightning-Linkc2a0technology.aspx>.

  • Chicago

    Expedeon. "Expedeon signs license agreement for use of Lightning-Link technology". News-Medical. https://www.news-medical.net/news/20190109/Expedeon-signs-supply-and-license-agreement-with-Cell-Guidance-Systems-for-use-of-Lightning-Linkc2a0technology.aspx. (accessed August 24, 2019).

  • Harvard

    Expedeon. 2019. Expedeon signs license agreement for use of Lightning-Link technology. News-Medical, viewed 24 August 2019, https://www.news-medical.net/news/20190109/Expedeon-signs-supply-and-license-agreement-with-Cell-Guidance-Systems-for-use-of-Lightning-Linkc2a0technology.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post
You might also like... ×
SYGNIS AG introduces new TruePrime apoptotic cell free DNA amplification kit